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I. Description 
Describes the policies and procedures to prevent healthcare workers from exposure to tuberculosis. 
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II. Rationale 
OSHA regulations require the employer to provide a written exposure control plan that covers the 
facilities’ policies and procedures to prevent transmission of tuberculosis in the workplace.  
Employees of the medical complex may have duties in more than one facility; therefore, this 
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exposure control plan is designed for all employees of UNC Health Care (UNCHC), Ambulatory 
Care Clinics, Community Based Centers, Campus Health Services, and the School of Dentistry.  
The Tuberculosis Control Plan is available on the UNC Health Care intranet (under Infection Control 
Policies) and on the University’s website (under Environment, Health and Safety). 
III. Policy 
A.  Risk Assessment and Departmental Responsibilities 
1. Risk  Assessment 
a.  A retrospective evaluation of a sampling of patients from whom M. tuberculosis is 
isolated will be conducted by Hospital Epidemiology periodically.  A written assessment, 
including an analysis of any nosocomial exposures, review of factors leading to 
exposures, and recommendations for preventing exposure in the future, will be provided 
to the Hospital Infection Control Committee. 
b.  On an ongoing basis, UNC Health Care Occupational Health Service (OHS) will maintain 
records of the results of evaluations of all UNCHC employees and UNCHC volunteers 
(except students) with occupational exposure to M. tuberculosis.  On a quarterly basis, 
OHS will provide a report to the Hospital Infection Control Committee that will include the 
number of UNCHC employees with occupational exposure, number of persons 
converting their TST after a known exposure, and any persons who have acquired active 
tuberculosis.  
c.  On an ongoing basis, OHS will maintain records of the results of all TSTs placed for 
screening purposes (new employees, routine screening of current employees).  On a 
yearly basis, OHS will provide a written breakdown of the TST positive rate (positive 
TSTs/total TSTs) to include TST conversion incidence by hospital location of 
employment or job description (whichever is more appropriate) to the Hospital Infection 
Control Committee. 
d.  For UNC-CH employees, University Employee Occupational Health Clinic (UEOHC) will 
maintain tuberculosis-screening records.  
2. Departmental  Responsibilities 
a.  It will be the responsibility of all department supervisors to note on an employee's yearly 
performance evaluation his/her adherence to the Tuberculosis Control Plan.   
b.  The Microbiology Lab will periodically provide a report of tuberculosis isolates with their 
susceptibilities to Hospital Epidemiology. 
c.  Departments with clinical staff have Departmental Safety Coordinators (DSC’s) who 
attend annual training from Environmental Health and Safety and Hospital Epidemiology.  
Training includes updates/revisions to the TB Control Plan.  The DSC’s are expected to 
communicate any updates to the staff in their departments.  Annual LMS training on TB 
covers topics as suggested by CDC guidelines and OSHA regulations.  UNC-CH DSC’s 
will receive monthly JCAHO/OSHA compliance reports.  The DSC will verify the 
accuracy of the report, assign new employees to the appropriate work unit, and ensure 
employees take the University’s on-line training or attend the instructor-led course. 
d.  Contracted employees must comply with all aspects of this TB Control Plan.  It is the 
responsibility of the contracted employee's employer to provide the required elements. 
B.  Occupational Health Responsibilities 
1.  Screening of New Employees Tuberculosis Control Plan 
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a.  All new employees will undergo evaluation for history of tuberculosis via a self-
administered questionnaire (see Appendix 7 and 7-1).  The following information will be 
ascertained for all employees: a) History of TST placement/blood test for latent TB 
infection (LTBI).  The dates of the most recent negative TST/blood test for LTBI will be 
recorded.  The date of the first positive TST/blood test for LTBI will be recorded, 
including circumstances of TST conversion/blood test.  Whenever possible, the mm of 
induration of any TST will be recorded.  b) History of treatment, if any, for a positive 
TST/blood test for LTBI.  History will include dates and types of treatment (specific 
drugs) including any side effects or drug toxicity.  History (with documentation, if 
possible) of all chest radiographs will be obtained.  c) History of active tuberculosis.  
History will include means of diagnosis, date of diagnosis, and dates and types of 
treatment (specific drugs) including any side effects or drug toxicity.  d) Presence of 
signs and symptoms of active tuberculosis (chronic cough, production of bloody sputum, 
fevers, night sweats, weight loss). 
b.  A TST (Mantoux TST) will be placed on all new employees unless one of the following is 
met: a) employee has a documented history of a TST reaction >10 mm in diameter; b) 
documented history of treatment for tuberculous infection or disease; c) documented 
allergy (i.e., immediate hypersensitivity) to TST; and d) current treatment with anti-
tuberculous drugs.  Employees with documented negative IGRA will have a TST 
placed.  TST will be placed on all employees who have undocumented histories of a 
positive TST or a history of having received BCG immunization.  A 2-step baseline TST 
shall be used for new employees who have not had a documented negative TB skin test 
result during the preceding 12 months*.  Controls (i.e., Candida, Mumps, or Tetanus) 
may be placed on employees who have underlying immunocompromising conditions or 
drug therapy (e.g., HIV positive, organ transplant with immunosuppression, 
chemotherapy).  The TST will be placed and read by the employee’s occupational health 
provider.   Documentation of outside TST administration and reading is accepted if the 
documentation is by a facility trained in public health/occupational medicine (e.g., 
Campus Health Services, public health department, occupational health department of 
other healthcare facilities, private physician, military).  TST is not contraindicated for 
pregnant employees. 
c.  For University employees, TSTs are placed and read by UEOHC unless specific 
arrangements, approved by the UNC Department of Environment, Health and Safety 
(UNCEHS), are made. 
d.  All employees will be counseled, at the time of initial evaluation, regarding the need to 
report all tuberculosis exposures to their Occupational Health Provider (OHP) and the 
need to obtain yearly TST tests.  All HCWs will be counseled regarding the need to 
report to their OHP the development of signs and symptoms consistent with active 
tuberculosis including: cough > 3 weeks, fever, night sweats, and unexplained weight 
loss. 
 
 
 
 
* The exception to this would be an employee with 2 documented negative TSTs within the last 12 months (one being within 
the last 3-6 months). 
e.  Employees with a reactive TST of unknown duration, a TST > 5 mm, positive blood test 
(IGRA), past history of INH prophylaxis, or symptomatic for possible TB will have a Tuberculosis Control Plan 
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baseline chest radiograph (unless the official chest x-ray report is available).  Employees 
are evaluated without regard to history of BCG use.  Employees with a reactive TST will 
be also evaluated for the possibility of active tuberculosis.  Such an evaluation may 
include a chest radiograph and the collection of 3 sputums for AFB smear and culture 
based on the presence of symptoms.  Sputums will be collected in the ID Clinic, in the 
Pulmonary Clinic in the ACC, or any other room meeting airborne isolation ventilation 
requirements.  An IGRA (blood test) may be ordered at the discretion of the OHS 
Medical Director if a new employee has received BCG, has a positive TST and a 
negative chest x-ray.   
f.  HCWs with suspected active tuberculosis will be relieved from work until active disease 
is ruled out by appropriate medical and microbiologic studies.  The employee will be 
counseled regarding the infectivity of active tuberculosis and the risk to others.  Grounds 
for removing a HCW from work may include, but not be limited to, the development of 
signs or symptoms suggestive of active tuberculosis and/or a chest radiograph 
consistent with active tuberculosis. 
g.  In accordance with the Respiratory Protection Program, employees must be assessed 
for the ability to wear respiratory protective devices.  For UNCHC employees, this is the 
joint responsibility of OHS and the Environmental Health and Safety Department.  For 
University employees, the respiratory protection program is the responsibility of UEOHC 
and the UNC Department of Environment, Health and Safety.  
h.  Annual fit testing for N-95 respirators is required by Federal law.  Healthcare facilities 
should be compliant with current OSHA regulations.  
2.  Annual Screening of Employees 
a.  All UNCHC employees should schedule an annual appointment with their OHP to have a 
TST placed.  Exclusion criteria for TST placement will be the same as Section III.B.1.b.  
Annual TST testing is highly recommended for UNC employees classified as having 
clinical duties or working in clinical facilities (i.e., those who fall under the immunization 
review program).   (“Employees of the McLendon Clinical Laboratories who process, 
concentrate, culture, or manipulate isolates of Mycobacterium tuberculosis or clinical 
samples submitted for culture of mycobacteria must have TST tests placed and read 
every six months.”) 
b.  Mandatory annual TST is not required by the State of NC DHHS regulations.  As per the 
CDC Guidelines, annual TST is recommended for employees in healthcare facilities that 
care for ≥ 3 patients with TB per year. 
c.  All employees will be counseled regarding the need to report all tuberculosis exposures 
to their OHP and the recommendation to obtain yearly TST tests or, if TST-positive, to 
review signs and symptoms with the OHS staff. 
d.  In the event that TST conversion following a known workplace source is documented, 
TST testing may be repeated on HCWs assigned to the infected source's work place at 
more frequent intervals than annually. 
e.  A report of a Mantoux TST or TB blood test administered by an outside healthcare 
facility will be accepted if the “Submission Form for Outside Tuberculin Skin Testing” 
(Appendix 3) is properly completed.  (This applies only to annual TST, not initial TST.)  
 
 
3.  Evaluation of the Pregnant Employee Tuberculosis Control Plan 
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a.  Pregnancy is not a contraindication to placement of a TST.  The same TST placement 
guidelines will apply to the pregnant HCWs as apply to the non-pregnant HCW. 
b.  Pregnant employees, if requesting counseling, will be notified that tuberculosis may 
progress more rapidly in pregnant individuals. 
c.  HCWs who meet the recommendations for therapy of latent tuberculosis infection (LTBI) 
or require therapy for active tuberculosis will be handled on an individual basis in 
conjunction with the patient and their primary physician.  INH and rifampin have been 
demonstrated to be safe in pregnancy by large-scale field trials.  There is no evidence 
that these agents cause infertility, fetal loss, or are teratogenic or oncogenic.  Therefore, 
in general, pregnant HCWs who meet the criteria for therapy of LTBI will be counseled to 
undergo such therapy.  Pregnant females with active tuberculosis will be counseled to 
undergo appropriate therapy. 
4. Outbreak  Investigations 
a.  Records of all patients from whom M. tuberculosis is isolated will be reviewed by 
Hospital Epidemiology to ascertain that proper infection control procedures were 
maintained throughout hospitalization and during outpatient visits.  In the event that 
HCWs or other patients experienced respiratory exposure to an infectious patient or 
HCW, every attempt will be made to notify exposed HCWs and patients.  Hospital 
Epidemiology will notify department heads/supervisors of the potential exposure for their 
employees.  It is the responsibility of the department heads/supervisors to identify and 
notify potentially exposed employees in their department, including contract workers 
assigned to that area.  The names of any exposed employees will be provided to the 
appropriate OHS.  Hospital Epidemiology will notify the patient's physician if a patient 
was exposed.  It will be the responsibility of an exposed patient’s primary UNC physician 
to notify an exposed patient and arrange for appropriate follow-up.  Evaluation of 
community exposures will be considered the responsibility of the local Health 
Department. 
b.  In the event that it is difficult to precisely define those who are potentially exposed (e.g., 
source case is an employee who works in an open area), a system of evaluating close 
contacts may be employed.  If close contacts reveal evidence of TST conversion, then 
progressively wider circles of individuals with lower amounts of exposure will be 
evaluated until evidence of transmission is not found.  The use of this concentric circle 
approach will be the responsibility of the Medical Director of Occupational Health and 
Hospital Epidemiology. 
c.  In some cases, investigations may not be instituted on the basis of a positive AFB smear 
if such a smear is likely to represent infection with NTM. 
d.  The Occupational Health Provider will be responsible for evaluating all healthcare 
workers (HCWs) with occupational exposure to M. tuberculosis.  Such an evaluation will 
include: whether an exposure occurred; presence or absence of signs or symptoms of 
active tuberculosis; and contraindications to a TST. 
e.  In all investigations of nosocomial transmission, attempts to identify the source will be 
made.  When the source of exposure is known, the drug susceptibility pattern of the M. 
tuberculosis isolated from the source will be determined in order to aid in the appropriate 
use of preventive therapy.   
f.  If no patient source is identified for a HCW who develops TST conversion and there is 
no evidence suggestive of an outbreak based upon the TST conversion rate of HCWs 
employed in the same department or on the same patient area, then additional TST 
testing of HCWs will not be instituted. Tuberculosis Control Plan 
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g.  Hospital Epidemiology will notify University Employee Occupational Health of possible 
nosocomial exposure for University personnel (including names, if documented on the 
medical record). 
h.  Hospital Epidemiology will notify students of possible nosocomial exposure if 
documented on the medical record.  When unable to contact the student, Hospital 
Epidemiology will notify Student Affairs/Campus Health Services of the exposure. 
i.  Hospital Epidemiology will notify the Orange County emergency medical service of 
possible nosocomial exposure of their HCWs.  It will be the responsibility of the EMS 
providers to contact the individuals and arrange appropriate evaluation.  EMS personnel 
outside of Orange County will be notified by their county Public Health 
Department. 
j.  Hospital Epidemiology will notify the department employing an outside contractor or 
outside student agency of possible nosocomial exposure.  The contracting department 
will notify the outside contractor or student agency.  It will be the responsibility of the 
outside contractor or student agency to contact exposed individuals and arrange 
appropriate evaluation. 
k.  All exposed HCWs will complete an Employee Incident Report following exposure and 
have a TST placed as soon as feasible (unless the HCW has a contraindication or an 
employee has had a TST placed and read within the previous 3 months).  A follow-up 
TST will be placed approximately 12 weeks after the exposure if the baseline TST was 
<10 mm.  If the exposure occurred more than 12 weeks prior to notification, only one 
follow-up TST needs to be done. 
5. TST  Testing 
a.  All TSTs will be placed using the Mantoux method. 
b.  Standard criteria will be used to place and interpret TSTs (see Appendix 4).  
c.  Results of TST tests will be recorded both in the individual HCW’s employee health 
record and in a retrievable aggregate database of all HCW TST test results. 
d.  In the event a TST results in >15 mm induration, topical treatment with a steroid-
containing cream may be recommended.        
e.  TST testing as required by NC State Regulation (15A NCAC 19A.0205) includes the 
following:          
i.  household and other close contacts of active cases of pulmonary and laryngeal 
tuberculosis        
ii.  persons reasonably suspected of having tuberculosis disease        
iii.  inmates in the custody of, and staff with direct inmate contact, in the Department of 
Corrections upon incarceration or employment, and annually thereafter         
iv.  patients and staff in long term care facilities upon admission or employment, using 
the two-step skin test method         
v.  staff in adult day care centers providing care for persons with HIV infection or AIDS 
upon employment, using the two-step skin test method         
vi.  persons with HIV infection or AIDS      
f.  TST testing is recommended for all pregnant women.  (Refer to Appendix 6: 
“Tuberculosis Diagnosis/Treatment” in the Infection Control Policy: “Labor and 
Delivery.”)        Tuberculosis Control Plan 
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g.  Post exposure tuberculin skin testing should be performed immediately after a known 
exposure with a follow up in 12 weeks after the exposure date. 
6.  Evaluation of Employees with Newly Recognized Positive TST Tests or TST Conversion 
a.  For all employees (excluding new employees) with a newly recognized positive TST test 
or TST conversion, a history of possible exposure will be obtained by OHS in an attempt 
to determine the potential source of TB exposure (see Appendix 4-1).  For HCWs who 
demonstrate TST conversion (based on follow-up TST done in conjunction with a known 
patient care exposure), Hospital Epidemiology will be notified to assess if the conversion 
may have occurred due to the patient care exposure.      
b.  Evaluation of family members will be recommended.  Such evaluations may be 
conducted by the local Health Department, private physicians, or UNC physicians via 
established medical clinics.        
c.  Employees with a newly recognized positive TST or TST conversion will be counseled 
about the possibility of re-infection, appropriateness of prophylactic treatment, and the 
need to report signs/symptoms of TB to their OHP.       
d.  Tuberculin skin tests that convert to positive during employment and employees 
diagnosed with active tuberculosis will be recorded in the OSHA 300 log.       
e.  For HCWs who demonstrate TST conversion (based on follow-up TST), the local health 
department should be notified only in the following circumstances: 1) the HCW has 
active tuberculous disease, 2) there is evidence that a close non-occupational contact 
was the source of the HCW’s TST conversion, or 3) the HCW appears to be part of a 
common source outbreak.  We do not need to routinely inform the local health 
department of all TST conversions.       
f.  An HIV test should be offered/encouraged to all persons with a positive TST (patient 
may refuse). 
7.  Occupational Health Coverage 
a.  The following healthcare workers will be evaluated by the UNCHC Occupational Health 
Service: UNCHC employees, house staff (physicians), volunteers and certain contract 
employees.  University employees will receive services from University Employee 
Occupational Health Clinic.       
b.  All students who obtain clinical experience at UNC clinical facilities shall receive their 
required initial screening through Campus Health Services or another approved 
healthcare facility (e.g., health department or a primary care physician’s office).  
The annual screening for individuals who have had a positive TST will be 
conducted at Campus Health Services.  Students with potential exposures will 
also be evaluated at Campus Health Services.       
c.  All contract employees who work directly with patients or in patient care areas must 
meet the screening requirements described in this policy.  It is the responsibility of the 
University or Hospital department hiring these employees to assure compliance with this 
policy.      
d.  It will be the responsibility of the occupational health provider to meet the current OSHA 
tuberculosis standards of education, record keeping, screening, fit-testing and outbreak 
evaluations.  Within the University, this is a joint responsibility of UEOHC and the UNC 
Department of Environment, Health and Safety. 
8. HCW  Counseling Tuberculosis Control Plan 
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a.  All HCWs will be counseled at the time of TST placement about the signs and symptoms 
of tuberculosis and the need for evaluation by their OHP should they develop these 
signs and/or symptoms.        
b.  At the time of TST testing, HCWs will be informed about the interpretation of TST test 
results, whether positive or negative, including the possible variable interpretations of 
induration of >5 mm, depending on immune status and exposure to persons with 
infectious TB. 
9.  Treatment of Employees for Latent TB Infection 
a.  Current CDC recommendations will be followed in evaluating TST size and deciding on 
the appropriateness of treatment for latent TB infection (LTBI).  All HCWs will be 
evaluated for active tuberculosis prior to beginning therapy.      
b.  Isoniazid (INH) 300 mg by mouth daily for 9 months is the current recommendation of 
therapy of LTBI.  Other therapies will be considered per current CDC/ATS guidelines.      
c.  Standard recommendations will be used in providing follow-up of HCWs taking INH.  
Appropriate follow-up will be done monthly.  HCWs with signs or symptoms of liver 
toxicity will be evaluated immediately.  All persons placed on LTBI therapy will be 
educated about the adverse reactions associated with these medications.    
d.  HCWs who refuse, or are unable to complete, LTBI therapy will undergo chest 
radiography at 0 and 12 months for the evaluation of active tuberculosis.       
e.  LTBI therapy may be offered at the discretion of the OHS Medical Director, to anergic 
HCWs who are known contacts of infectious TB patients and for those groups in which 
the prevalence of TB infection is high (i.e., >10%).      
f.  The decision to use LTBI therapy in the peripartum period will be made on a case-by-
case basis by the OHS Medical Director in conjunction with the employee's primary 
physician and the employee, depending on the employee's estimated risk of progression 
to active disease. 
10. Treatment of UNC-CH and UNC Health Care Employees with Active Tuberculosis 
a. Employees with possible or documented active tuberculosis will immediately be relieved 
from all work activities.  When indicated, hospitalization will be recommended. Leave 
from work will be handled according to personnel policies.      
b. All  employees with active tuberculosis will be offered anti-tuberculous therapy based on 
current CDC recommendations.  In general, a four-drug regimen will be used, pending 
susceptibility testing of the infecting strain.  Directly observed therapy will be done or 
arranged by the Health Department.      
c.  Employees refusing therapy will be relieved of all work activities and reported to the 
Health Department.      
d.  All employees with active tuberculosis will be counseled regarding the risk of disease 
among household contacts. 
11. Return to Work for Employee with Active Tuberculosis 
a.  All HCWs with recent active tuberculosis must be evaluated by their OHS prior to 
returning to work.       
b.  Prior to returning to work, the employee must have all of the following documented:       
i.  Appropriate therapy for at least two weeks      
ii.  Clinical improvement      Tuberculosis Control Plan 
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iii.  Sputum smears consecutively negative x 3 for mycobacteria      
iv.  Stable or improved chest radiograph 
12. Immunocompromised HCWs 
a.  Counseling via the OHS will be available for immunocompromised healthcare workers 
regarding their risks for acquiring tuberculosis.      
b.  Immunocompromised healthcare workers will be offered reassignment from areas where 
patients with M. tuberculosis frequently receive care (ID Clinic/Pulmonary units). 
C.  Management of Patients with Known or Suspected Tuberculosis 
1.  Recognition of Patients with Potential Tuberculosis 
a.  A diagnosis of tuberculosis should be considered in any patient with persistent cough 
(>3 weeks duration) or other signs and symptoms compatible with tuberculosis such as 
complaints of bloody sputum, night sweats, weight loss, anorexia, or fever.  All patients 
with signs and symptoms of tuberculosis should be placed on Airborne Precautions until 
active tuberculosis is excluded.  (Refer to Appendix 10 for algorithm.)      
b.  Healthcare workers should realize that groups at high risk for tuberculosis include the 
following: HIV-infected persons, immigrants from countries with high endemic rates of 
tuberculosis, migrant farm workers, persons who have been incarcerated, 
immunocompromised persons (e.g., solid organ transplant), persons with a history of a 
positive tuberculin skin test, contacts of persons who have had active tuberculosis, and 
homeless persons.  In North Carolina, the prevalence of tuberculosis increases with age 
(especially high with persons over age 60) and is higher in non-whites and males.      
c.  Appropriate diagnostic studies should be conducted on all patients with signs or 
symptoms consistent with tuberculosis.  Such studies include tuberculin skin tests, 
sputum for mycobacterial smears and cultures, chest radiography, and chest 
tomography.  Additional tests may also be required including: bronchoscopy, induced 
sputum for AFB smear and culture, nasogastric aspirate for AFB culture (pediatric 
patients), and/or bone marrow biopsy.  All patients with a positive tuberculin test, blood 
test or chest radiography suggestive of infectious tuberculosis should be evaluated for 
active tuberculosis.  It will be the responsibility of all Clinic Directors, the Director of 
Emergency Medicine, and inpatient Clinical/Medical Directors to develop a mechanism 
for screening of all patients for active tuberculosis.  When patients with previously 
diagnosed TB are readmitted to UNCHC or visit outpatient areas before confirmation of 
complete cure, they should be placed on Airborne Precautions until infectiousness 
active disease has been ruled out. 
2.  In-Patient Management of Patients 
a.  Isolation (When to Isolate) 
i.  All patients with known or suspected pulmonary tuberculosis, laryngeal TB, or miliary 
TB) will be placed on Airborne Precautions.  Patients with open/draining wounds 
or who have wound drains in place (e.g., JP) must be placed on Airborne 
Precautions.  All patients with a gastric aspirate that is culture positive or culture 
positive for AFB and all patients with known or suspected miliary TB whose 
respiratory tract cultures are positive for AFB will be placed on Airborne Precautions.  
Such isolation will include the wearing of respiratory protective devices by all persons 
entering the patient's room.  (See exception for patient ≤15 yrs of age below - 
paragraph ix.)         Tuberculosis Control Plan 
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ii.  For patients with AIDS and a recent history (≤ 1 yr) of disseminated non-tuberculosis 
mycobacterium, isolation is not needed if the attending physician does not suspect, 
test for, or treat the patient for TB.  If MTB is suspected or in the differential diagnosis 
the patient must be placed on isolation until diagnosed or ruled out.        
iii.  Patients with CF and a first positive isolate (smear or culture) for AFB must be 
placed on Airborne Isolation until TB is excluded.  Patients with CF or other known 
chronic non-tuberculous mycobacterial colonization/infection and a positive history 
for nontuberculous mycobacterium do not require Airborne Isolation for new positive 
AFB isolates unless TB is suspected or is in the differential diagnosis or the 
physician treats the patient for TB.  In such cases, the patient will be on Airborne 
Isolation until TB is excluded.           
iv.  For patients for whom specimens for AFB are ordered as a component of a 
procedural protocol (i.e., organ transplantation, CF/thoracic patient bronchoscopy), 
Airborne Isolation is not required. 
v.  For patients with pleural TB who have negative sputum/respiratory smears, it 
is considered extrapulmonary and Airborne Precautions is not needed.                  
b.  Isolation Guidelines   
i.  Patients with known or suspected TB will be placed in isolation rooms that meet the 
CDC recommendations.  (See section III.E.1. - "Isolation Rooms that Meet CDC 
Recommendations.”)  If, in the opinion of the patient’s attending physician, moving 
the patient is medically contraindicated, the Medical Director (or designee) of 
Hospital Epidemiology must be consulted.  Hospital Epidemiology will:  (1) notify the 
appropriate nursing supervisor if moving the patient to a room meeting TB isolation 
ventilation requirements is medically contraindicated and (2) advise staff regarding 
appropriate engineering controls such as use of a portable HEPA unit and 
modification of ventilation in the patient’s room to optimize air exchange rates.                   
ii.  Ventilation requirements will include: single room, negative air pressure (corridor 
positive with respect to the room), >6 air exchanges per hour, and direct out-
exhausted air.  The corridor door must remain closed except when entering or exiting 
the room.  Negative pressure should be monitored with a tissue test and recorded 
daily by nursing personnel while the room is being used for Airborne Precautions.  
For isolation rooms with an anteroom, check the air pressure at both the hallway 
door and the inner door of the anteroom.  For isolation rooms with more than one 
entry door, check the pressure at both doors.  The results of daily pressure 
monitoring should be noted in the patient care record.  If positive or neutral pressure 
is detected in an Airborne Isolation Room, Maintenance will be notified to correct the 
problem as soon as possible.  While waiting, a HEPA unit should be placed inside 
the patient’s room at the door. 
iii.  Airborne Precautions may be initiated by any physician or an Infection Control 
Professional (Department of Hospital Epidemiology).  In addition, Airborne 
Precautions may be initiated by a triage nurse, any inpatient nurse, a physician's 
assistant or nurse practitioner (such isolation orders shall be valid for 24 hours during 
which time a physician must co-sign the orders or enter an order for discontinuing 
isolation). 
iv.  Nursing staff will educate all patients placed on Airborne Precautions emphasizing 
the need to adhere to the UNCHC Isolation Precautions guidelines.  Patients who 
refuse to adhere to Airborne Precautions will be reported to the Orange County 
Health Department.  When applicable, legal action will be taken to enforce Tuberculosis Control Plan 
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appropriate Airborne Precautions.  UNCHC Security will aid in enforcing court 
ordered isolation.  Alternatively, patients refusing to adhere to Airborne Precautions 
will be transferred to State facilities capable of managing such patients.  Psychiatric 
consultation will be obtained to assist in such transfers. 
v.  Diagnostic procedures should be performed in the isolation room whenever possible.  
In the event a patient with known or suspected tuberculosis must be transported to 
another hospital location for diagnostic or therapeutic studies or therapy, the patient 
shall wear a surgical mask covering the nose and mouth.  Notify Hospital 
Epidemiology if the patient is a child/infant who is unable to wear a mask.  The 
person(s) transporting the patient does not need to wear respiratory protection 
outside of the isolation room as long as the patient wears a mask.  If the patient 
being transported requires mechanical ventilation, a “heat moisture exchanger with 
filter” (HME) will be applied to the exhalation port on the ventilator.  If the patient 
requires bag-mask ventilation, the HME will be removed from the exhalation port on 
the ventilator and placed on the endotracheal tube connector.  Efforts should be 
made to schedule the procedure at a time when it can be performed rapidly and 
when waiting areas are less crowded.  The receiving area will be notified by 
personnel at the site of the patient's origin that the patient is on Airborne 
Precautions.  If the procedure request form or ordering screen provides for indication 
of isolation precautions, the appropriate box should be checked. 
vi.  Patients with MDR-TB or XDR-TB will remain on Airborne Precautions throughout 
their hospitalization because of their tendency for treatment failure or relapse. 
vii. Pediatric patients with suspected or confirmed TB should be evaluated for potential 
infectiousness as are adults, on the basis of symptoms, sputum AFB smears, 
radiographic findings, and other criteria.  Those with pulmonary or laryngeal TB will 
be placed on Airborne Precautions until they are determined to be non-infectious.  
Consultation with a pediatric infectious disease specialist is recommended when TB 
in a child is suspected. 
viii. An approved portable HEPA filter unit will be placed in a single room in the following 
areas when occupied by a patient with known or suspected tuberculosis:  Operating 
Room, and certain Intensive Care Unit rooms (when all TB isolation rooms are 
occupied by patients requiring Airborne Precautions).  Negative pressure will be 
maintained with exception of the operating rooms including those in Labor and 
Delivery.  Personnel entering such rooms will wear personal respiratory protection 
devices.  
ix.  Women with tuberculosis who have been treated appropriately for 2 or more weeks 
and who are not considered contagious may breastfeed.  Women with tuberculosis 
disease suspected of being contagious should refrain from breastfeeding or any 
other close contact with the infant because of potential transmission through 
respiratory tract droplets.  She may pump breast milk that may then be fed to the 
infant by bottle by a noninfectious person.  Mycobacterium tuberculosis rarely 
causes mastitis or a breast abscess, but if a breast abscess caused by M. 
tuberculosis is present, breastfeeding should be discontinued until the mother no 
longer is contagious. 
x.  If the patient must temporarily leave the Airborne Precautions room, the door must 
be kept closed for a minimum of 30 minutes prior to anyone entering without wearing 
a respiratory protection device.  Likewise, the door should remain closed for a 
minimum of 30 minutes when a patient is discharged from an Airborne Precautions Tuberculosis Control Plan 
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room.  The 30 minutes time period will allow the room ventilation system to remove 
any droplet nuclei. 
xi.  Patients with known or suspected tuberculosis should not ambulate outside the 
isolation room for therapeutic reasons.  Hospital Epidemiology must approve any 
exceptions to this policy. 
xii. When a patient from a prison is on Airborne Precautions, the accompanying 
Department of Corrections personnel will wear a respirator while they are present in 
the patient’s room.  Fit testing is the responsibility of the Department of Corrections. 
xiii. Refer to Appendix 9 for the “Procedure for Instituting Airborne Precautions When the 
Patient is Housed in a Multi-Bed Room.”  
c.  Isolation Guidelines When Molecular Direct Detection (PCR) is Done on AFB 
Smears 
i.  Molecular Direct Detection (PCR) testing is not ROUTINELY run on all first time 
positive smears.  Direct Detection is run only on request of the ordering physician, 
the Infectious Disease Service, or Epidemiology (i.e., Directors, Associate Director, 
Epidemiologist, ICPs).  (See Appendix 2, section II: “Special Requests.”) 
ii.  Smear positive specimens are submitted to Mayo Medical Laboratories on 
weekdays; Mayo performs TB Direct Detection daily, Monday-Friday, and reports are 
issued the day of the run.  Therefore the turnaround time for TB Direct Detection is 
approximately 2-5 working days.  Since the sensitivity of the TB direct detection for 
any smear positive specimens is approximately 93% 97%, a patient can be removed 
from isolation based upon a negative result from a respiratory tract specimen if, in 
the opinion of the attending physician, TB is no longer in the differential diagnosis, 
and the clinical picture and X-rays are not suggestive of pulmonary active TB.  
Patients with a positive TB (Direct Detection) should remain on Airborne Precautions 
until the patient is appropriately treated for TB (minimum of 2 weeks of treatment), 
has had 3 consecutive negative smears (unobtainable induced sputum will count as 
a negative smear), clinical improvement, or cultures demonstrate a non-tuberculous 
mycobacteria. 
iii.  DNA probes are no longer performed in UNC Clinical Microbiology Lab.  See Special 
Requests in Appendix 2 for information on 16SrRNAgene sequencing. 
d.  Isolation: Visitors 
i.  Patients with known or suspected TB will be allowed limited visitors.  All visitors must 
be able to comply with Airborne Precautions.  All visitors must wear surgical masks 
or N-95 respirators (refer to exception in d.iii. below).  They should be instructed 
on use of the mask or N-95 respirator, as well as Airborne Precaution rooms.  This 
includes 24-hour caregivers (persons without recompense and who are not UNCHC 
employees or volunteers) and other visitors who may stay in adult or pediatric patient 
rooms for extended periods of time.  Visitors under the age of 12 years must be 
screened for contagious illnesses or exposures before being allowed to enter an 
Airborne Precautions room.  Refer to the UNCHC Administrative Policy: Visiting 
Hours and Regulations. 
ii.  Individuals visiting inpatients (all patients > 15 years of age) on Airborne Precautions 
for TB, who have any symptoms of TB including a mild non-productive cough ≥ 3 
weeks duration, will be asked to provide written evidence that they do not have 
active tuberculosis.  A physician or the local health department must provide the 
verification.  Visitors refusing to obtain the TB evaluation and verification of absence Tuberculosis Control Plan 
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of disease will be barred from admittance to all UNCHC facilities.  UNCHC Security 
will have authority to enforce this provision.  (See Appendix 10: “Guide to Airborne 
Isolation Precautions for Suspect TB Patients.”)                         
iii. For  patients  ≤15 years of age with suspected or diagnosed TB, all household 
members and close contacts must provide written verification of the absence of 
disease prior to visitation regardless of signs/symptoms of illness.  Written 
verification should include: 1) absence of the following symptoms: persistent cough 
(≥ 3 weeks duration), hemoptysis, night sweats, weight loss and fever; 2) a negative 
Mantoux TST read by a trained HCW; and 3) a negative chest radiograph if 
indicated.  Primary care givers (e.g., parents) may visit before the evaluation has 
been done but they must wear a surgical mask at all times when outside the child’s 
room.  They may remove their mask only within their child’s isolation room or until 
they have documentation that they do not have active TB.  The primary care giver 
must complete their TB evaluation within 3 working days of the child’s admission.  
(See Appendix 10: “Guide to Airborne Isolation Precautions for Suspect TB 
Patients.”) 
iv.  If a primary care giver, household member, or other close contact is found to have 
active TB, they may not visit until they have written documentation that they are no 
longer infectious.  Their local health department or an attending physician of the 
UNCHC must provide the verification.  If the primary care giver has been released 
from home isolation but is still undergoing directly observed therapy (DOT), the 
Orange County Health Department will assume responsibility for delivering and 
observing the administration of the antibiotics.  This can be arranged by having the 
primary care giver’s local health department contact the Orange County Health 
Department. 
e.  Discontinuation of Isolation       
i.  For patients with suspected tuberculosis, Airborne Precautions may be discontinued 
when a diagnosis other than pulmonary tuberculosis is confirmed and tuberculosis is 
no longer considered in the differential diagnosis OR when three sputum smears 
obtained 8 hours apart and all 3 are reported as negative by the Microbiology 
Laboratory and tuberculosis is no longer considered in the differential diagnosis. 
Each failed sputum induction equals one negative smear.  The sputum inductions 
must be done at least 8 hours apart (ideally, one of the three will be an early morning 
sample).  A bronchoscopy specimen can count as a valid single sample.  Also with 
patients < age 3, Airborne Precautions can be discontinued if a BAL is negative for 
AFB by smear.  A physician's order is required to discontinue isolation.     
ii.  For patients with a sputum smear, gastric aspirate culture, or culture positive for 
mycobacteria, Airborne Precautions may be discontinued when the cultures are 
finalized as negative for M. tuberculosis.  Airborne Precautions may be discontinued 
if the TB Direct Detect test is negative for MTB on sputum samples which are smear 
positive providing the clinical picture and chest radiographs are not highly 
suggestive of TB AND TB is no longer in the differential diagnosis.  Discontinuing 
isolation using these criteria requires the approval of the patient’s attending 
physician.        
iii.  For patients with pulmonary tuberculosis, Airborne Precautions may be discontinued 
only when the patient is on effective therapy for at least 2 weeks, is improving 
clinically, and all 3 sputum smears are negative for AFB done at least 8 hours apart 
(ideally, one of the three will be an early morning sample).  The negative sputums or 
failed inductions must be obtained in consecutive order.  If any sputum specimens Tuberculosis Control Plan 
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are AFB positive, wait 2 weeks and repeat a series of 3 AFB sputums.  When all 3 
smears are negative in the series and the patient has met the additional criteria 
stated above, the patient may then be removed from Airborne Isolation.  For pediatric 
patients, the specimens may be gastric aspirate culture when induced sputum 
cannot be obtained.  No smears should be conducted on gastric aspirates.       
iv.  For patients with soft tissue open/draining lesions with a positive smear for 
mycobacteria, Airborne Precautions may be discontinued when the cultures are 
finalized as negative for M. tuberculosis, the Direct Detect test is negative, or the 
lesions have closed and stopped draining.       
v.  For patients with soft tissue open/draining lesions with M. tuberculosis, Airborne 
Precautions may be discontinued when the patient is on 2 weeks of effective 
therapy, is improving clinically, and smears obtained from wound drainage are 
negative for AFB on three separate occasions at least 8 hours apart OR when the 
wound is closed, no longer draining, or drain has been removed.       
vi.  For patients with extrapulmonary TB (e.g. TB meningitis), Airborne Precautions are 
not required unless they have symptoms of pulmonary or draining soft tissue TB 
infection. 
vii. For patients with a history of negative smear, culture positive TB, Airborne 
Precautions may be discontinued if the patient has been treated for a minimum 
of 2 weeks and has demonstrated clinical improvement.    
3. Discharge  Planning 
a.  Will include at a minimum: a) a confirmed appointment with the provider who follows the 
patient until cure, b) sufficient medication to take until the out-patient appointment, c) 
placement into case management of the health department, and d) evaluation of 
possible immunocompromised persons or children < 5 years old in the home.  (Note:  
Since appointments at UNC clinics can only be made during normal business hours, 
patients being discharged on weekends or late shifts should have their follow-up 
appointments made prior to discharge.)    
b.  Patients who may be infectious at the time of discharge should only be discharged to 
facilities with tuberculosis isolation capabilities or to home.  They should not be 
discharged to home if there are persons in the household who are at high risk for 
acquiring active tuberculosis (i.e., children less than or equal to 5 years of age, persons 
infected with HIV, or persons who are immunocompromised).  Patients going home in a 
public conveyance (e.g., van) must be instructed to wear a mask and keep it on for the 
duration of the trip.  They should be instructed to refrain from going to a public place 
prior to consulting with the health department.       
c.  It will be the responsibility of the physician who writes the discharge orders to adhere to 
these provisions. 
4.  Management of Patients in the Ambulatory Care Clinics (any Outpatient/Community-Based 
Settings) 
a.  Patients with signs and symptoms suggestive of tuberculosis should be evaluated 
promptly to minimize time spent in ambulatory care waiting areas (see Appendix 5).  
Such patients should have Airborne precautions applied while the diagnostic evaluation 
is being conducted.  It will be the responsibility of the clinic director or an attending level 
physician to designate clinic personnel who will be responsible for determining whether:          
i.  airborne precautions should be implemented (Hospital Epidemiology can be 
consulted via pager: 216-6652), and      Tuberculosis Control Plan 
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ii.  the patient should be referred immediately to the Pulmonary, Pediatric Specialty or 
Infectious Disease Clinic for evaluation for active tuberculosis. 
b.  TB precautions consist of the following: 
i.  placement of the patient in a separate waiting area apart from other patients (as 
soon as possible in a room meeting TB isolation requirements);      
ii.  giving these patients N95 respirators or surgical masks, instructing them to keep 
their masks on;   
iii.  and giving the patients tissues to use for covering a cough or sneeze. 
c.  Referral to Pulmonary Medicine, Infectious Disease Clinic, or Pediatric Specialty Clinic 
i.  Consideration should be given to referring all patients suspected or known to have 
tuberculosis to their local health department for free treatment.  When active TB has 
been ruled out or appropriately treated, then they can continue care at UNC 
outpatient clinics.      
ii.  Pulmonary Clinic, Pediatric Specialty or the Infectious Disease Clinic: Patients at 
high risk for HIV infection are to be sent to the Infectious Disease Clinic.  Patients 
seen in the Family Practice Center with either known or suspected TB should be 
referred to the ID Clinic or Pulmonary Disease Clinic for evaluation until proven 
noninfectious.  Patients under the age of 19 years should be referred to the Pediatric 
Specialty Clinic.      
iii.  Infectious Disease Clinic:  call 216-0626 (digital beeper) and the Infectious Disease 
Fellow on call will respond.  Infectious Disease Clinic is located on the first floor of 
UNC Memorial Hospital.      
iv. Pulmonary  Medicine Clinic:  call 6-4131, 6-6838, or 6-4005 and ask for a Pulmonary 
consult.  Pulmonary Medicine Clinic is located on the third floor of the Ambulatory 
Care Center.      
v.  Pediatric Specialty Clinic:  call 6-1401 for appointments or call the Paging Operator 
at 6-4113 and ask for the on-call Pediatric Infectious Disease Consultant. 
5. Cough-Inducing  Procedures 
a.  Cough-inducing procedures should not be performed on patients who may have active 
tuberculosis unless absolutely necessary.       
b.  All cough-inducing procedures performed on patients who may have infectious 
tuberculosis must be performed in a room meeting the ventilation requirements for 
Airborne Precautions.  Airborne Isolation rooms are available in the Infectious Disease 
Clinic, Peds Specialty Clinics, and ED.       
c. Healthcare  workers  will wear a respirator when present where cough inducing 
procedures are being performed on patients with known or suspected infectious 
tuberculosis.       
d.  After completion of cough-inducing procedures, patients with known or suspected 
infectious tuberculosis (including patients at high risk of tuberculosis such as HIV-
infected patients) should remain in the isolation room and not return to common waiting 
areas.  They will be given tissues and instructed to cover the mouth and nose when 
coughing.  If they must recover from sedatives or anesthesia following procedures such 
as bronchoscopy, they must be monitored in a separate Airborne Precautions room, and 
not in a common area such as a recovery room.  Upon discharge from the hospital, 
instruct the patient to wear a mask until they exit the hospital.       Tuberculosis Control Plan 
IC 0060    Page 16 of 47 
e.  At least 30 minutes should pass before a room in which a cough-inducing procedure has 
been performed on a patient with known or suspected infectious tuberculosis is utilized 
for another patient. 
6. Laboratory  Diagnosis 
a.  The UNCHC Microbiology Laboratory will utilize the most rapid or sensitive method 
available for the identification of mycobacteria (e.g., fluorescent microscopy for AFB 
smears).             
b.  Smears sent to the UNCHC Microbiology Laboratory will be processed according to lab 
policy.  Smears may be processed on a "stat" basis if requested by an Infectious 
Disease fellow or attending physician and approved by the Microbiology Lab Director on 
call.  If performed, stat smears are made from direct specimens (i.e., unconcentrated) 
and therefore have very low sensitivity.               
c.  All positive smears and cultures for M. tuberculosis or Mycobacterium spp. will be 
reported immediately to the requesting physician and by the printing of an Instant Report 
from the Laboratory Information System to the Hospital Epidemiology printer.  After 
hours on weekdays (smears not done on weekends), new positive smears are printed to 
the Epidemiology printer and a voice-mail message is left stating that the report has 
been printed. All send-out lab results (TB-PCR) will be faxed to Hospital Epidemiology at 
966-1451.          
d. All  patients  with  M. tuberculosis will have their isolate tested for drug susceptibility 
susceptibilities. 
7. Reporting 
a.  Clinical Settings on the UNC Campus 
i.  Physicians are responsible for completing the Communicable Disease Report 
Card/Form and for seeing that it is sent to Hospital Epidemiology (Via tube system 
#704 or CB 7600).  Hospital Epidemiology will send the card to the Health 
Department.         
ii.  Hospital Epidemiology personnel will contact the patient's local health department 
(by telephone) once a patient is known to be infectious with M. tuberculosis.      
iii.  All positive cultures and smears for M. tuberculosis will be reported by the Clinical 
Microbiology Laboratory by fax to the North Carolina State Division of Epidemiology 
on the day of recognition. 
b. Community-Based  Practices   
i.  Physicians are responsible for notifying the health department of the county where 
the TB patient resides.  This should be done by telephone within 24 hours. 
 
 
8.  Additional Considerations for Selected Areas 
a. Ambulatory  Surgery  Center - Patients with known or suspected TB will not be operated 
on in the Ambulatory Surgery Center.     
b. Operating  Room - Elective operative procedures on patients with known or suspected 
TB should be delayed until the patient is no longer infectious.  When emergency cases 
must be performed, the doors to the operating room should be closed and traffic in and 
out of the room should be kept to a minimum.  Attempts should be made to perform the Tuberculosis Control Plan 
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procedure at a time when other patients are not present in the operative suite (i.e., end 
of day) and when a minimum number of personnel are present.  A patient with known or 
suspected tuberculosis who is brought to the holding area for surgery must go directly 
into an operating room.  If the operating room is not ready to receive the patient, the 
patient must be placed in a negative pressure isolation room in PACU.  Personnel 
present when operative procedures are performed on patients who may have infectious 
TB should wear a respirator rather than a standard surgical mask.  The anesthesia 
machine should be equipped with a disposable anesthesia filter (Filtaguard).  Portable 
HEPA units will be used in the Operating Room (see III.E.2.b).     
c. Autopsy  Room - The autopsy room should be at negative pressure with respect to 
adjacent areas, with room air exhausted directly to the outside of the building.  12 air 
exchanges per hour is recommended.  Respiratory protection devices should be worn by 
personnel while performing autopsies on patients who were known or suspected to have 
TB.  A tissue test should be done to confirm negative pressure.    
d.  Dental Clinic and School of Dentistry - No specific dental procedures have been 
classified as "cough-inducing", however, since aerosols of oral fluids and materials may 
be generated, and, on occasion, coughing may be stimulated by oral manipulations, 
additional considerations appear prudent in a dental setting.  Dental HCWs should 
routinely ask all patients about a history of TB disease and symptoms suggestive of TB.  
Patients with a history and symptoms suggestive of TB should be promptly referred for 
evaluation for possible infectiousness.  Elective dental treatment should be delayed for 
patients known or suspected to have TB until the patient is no longer Infectious.  If 
urgent dental care must be provided for a patient with known or suspected TB, Airborne 
Precautions practices must be employed.      
e.  Ground and Air Transport Service - During transport of patients with known or suspected 
TB, the patient will wear a surgical mask.  Alternatively, personnel will use TB 
respirators.  The ambulance windows should be kept down as much as possible to allow 
for dilution ventilation.  If the patient being transported requires mechanical ventilation, a 
“heat moisture exchanger” (HME) will be applied to the exhalation port on the ventilator.  
If the patient requires bag-mask ventilation, the HME will be removed from the 
exhalation port on the ventilator and placed on the endotracheal tube connector.  
f. Obstetrical  Patients – TST skin testing and care of OB patients with suspected/known 
TB is outlined in the Labor and Delivery Infection Control Policy.     
g. Home  Health/Hospice – Home Health and Hospice will be notified of patients with 
known/suspected TB at the time of the referral. 
D. Education 
1. Training  Requirements 
a.  All HCWs who have the potential for exposure to M. tuberculosis and all employees 
located in healthcare facilities will receive education about TB that is appropriate to their 
job category.  Training shall be conducted before initial assignment and annually.  
Training can be accomplished in a variety of mechanisms.  For employees of UNCHC, 
this training is provided through the Learning Management System (LMS).       
b.  For University employees, training is provided through the University’s on-line self-study 
or Instructor-led course.  New UNC-CH employees are required to attend the 
University’s Clinic Environmental Safety Orientation Class.      
c.  Although the level and detail of this education may vary according to the job description, 
the following elements should be included in the education of HCWs: Tuberculosis Control Plan 
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2.  Elements of Education 
a.  The basic concepts of TB transmission, pathogenesis, and diagnosis, including the 
difference between latent TB infection and active TB disease, the signs and symptoms 
of TB, and the possibility of reinfection in persons with a positive TST test.   
b.  The potential for occupational exposure to persons with infectious TB in UNCHC’ 
facilities, including the prevalence of TB in the community and UNC Hospitals, the ability 
of UNCHC to appropriately isolate patients with active TB, and situations with increased 
risk of exposure to TB.   
c.  The principles and practices of infection control that reduce the risk of transmission of 
TB, including the hierarchy of TB infection control measures and the written policies and 
procedures of UNCHC.  Site-specific control measures should be provided to personnel 
in areas needing measures in addition to the basic control program.   
d.  The purpose of TST testing, the significance of a positive result and the importance of 
participation in the skin test program.   
e.  The principles of preventive therapy for latent TB infection.  Indications, use, and 
effectiveness, including the potential adverse effects of drugs.   
f.  The responsibility of the HCW to seek medical evaluation promptly if symptoms develop 
that may be due to TB or if TST conversion occurs in order to receive appropriate 
evaluation and therapy and to prevent transmission of TB to patients and other HCWs.     
g.  The principles of drug therapy for active TB.    
h.  The importance of notifying the facility if diagnosed with active TB so that appropriate 
contact investigation can be instituted.   
i.  The policies of UNCHC regarding confidentiality of HCW records.   
j.  The higher risk posed by TB in individuals with HIV infection or other causes of severely 
impaired cell-mediated immunity including: 1) the more frequent and rapid development 
of clinical TB after infection with M. tuberculosis; 2) the differences in the clinical 
presentation of disease; and, 3) the high mortality rate associated with MDR-TB disease 
in such individuals.   
k.  The potential development of cutaneous anergy as a result of impaired immune function, 
measured by CD4+ T-lymphocyte count declines.      
l.  The UNCHC policy on voluntary work reassignment options for immunocompromised 
HCWs. 
E. Engineering  Controls 
1.  Isolation Rooms that Meet CDC Recommendations 
a.  Refer to Airborne Isolation Rooms for a complete list of Airborne Precaution rooms 
within UNCHC, which is kept by Bed Management, Plant Engineering, and Hospital 
Epidemiology.  Plant Engineering will evaluate the isolation rooms every 12 months to 
verify ventilation meets the CDC recommendations. 
2.  Use of Portable HEPA Units / Local Exhaust Ventilation Devices 
a.  All cough inducing procedures should ideally be performed using local exhaust 
ventilation devices such as booths or done in rooms that meet the ventilation 
requirements for Airborne Precautions.     
b. Two portable HEPA units will be used in the operating room for cases having known or 
suspected pulmonary tuberculosis or when a body cavity infected with M. tuberculosis is Tuberculosis Control Plan 
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entered or disrupted.  The unit will be turned on (highest setting) prior to initiating the 
procedure.  One unit will be placed near the patient’s head and one unit will be placed 
near the entrance door.  The unit should be run for 30 minutes following the patient 
leaving the room. 
F. Respiratory  Protection 
1.  All HCWs entering an enclosed area of a patient who has known or suspected tuberculosis 
or who are present when cough inducing procedures are performed on patients with known 
or suspected TB will wear a respiratory protective device (respirator) meeting OSHA 
recommended performance criteria.  Such a device should be placed prior to entering the 
room and removed only after leaving the room.  HCWs who must wear a respirator will be 
included in the Respiratory Protection Program and fit tested.      
2.  Policies and procedures regarding the use of respirators are incorporated in the Respiratory 
Protection Program. 
G.  Respiratory Protection Program 
1.  Assignment of responsibility:  UNCHC Industrial Hygienist, Department of Environmental 
Health and Safety will manage The UNCHC program.  The respiratory protection program 
for UNC-CH employees is managed by the UNC Department of Environment, Health and 
Safety.     
2.  For UNCHC employees, Departmental Safety Coordinators (DSC) will be trained by the 
Industrial Hygienist to fit test designated employees within their departments.  "Saccharin 
Taste Test” fit testing will be utilized.  Respirator fit testing of UNC-CH employees will be 
performed by UEOHC and the UNC Department of Environment, Health and Safety.  A 
quantitative fit-testing method will be utilized for University employees.     
3.  Fit testing will be limited to personnel who require the use of respirators as indicated in 
III.F.1.  These personnel will be limited to locations where known or suspected patients with 
TB are most concentrated (Pulmonary/Infectious Disease Service nursing units and all 
Bronchoscopy suites).     
4.  Medical Screening:  HCWs will be evaluated to determine whether fit testing is safe.  The 
screening process will be performed utilizing a general screening questionnaire for medical 
conditions that may compromise the safety of fit testing or respirator use.  The questionnaire 
will be given to all employees at the time of employment and will be reviewed by the Medical 
Director of the Occupational Health Provider or his designee.  The Medical Director or his 
designee will identify employees who need further evaluation, which may include a physical 
examination.  (See Appendices 6-1: “Respirator Medical Evaluation Form” and 6-2: 
“Respiratory Protection Data”.)    
5.  Fit testing:  A fit test is used to determine whether a respiratory protective device adequately 
fits a particular HCW.  Fit tests can detect only the face seal leakage that exists at the time 
of the fit testing.  Face seal leakage can result from factors such as incorrect facepiece size 
or shape, incorrect or defective face piece sealing-lip, beard growth on a wearer, 
perspiration or facial oils that can result in facepiece slippage, failure to use all the 
headstraps, incorrect positioning of a facepiece on a wearer's face, incorrect headstrap 
tension or position, improper mask maintenance, and mask damage.  HCWs who fail the fit 
test will be re-fitted using another type of respirator that meets OSHA requirements.  
Employees using N95 respirators for protection against M. tuberculosis are fit-tested initially 
upon hiring, annually, and as specified by the UNCHC Respiratory Protection Program, 
Policy Number 55, located on the Hospital’s intranet web site.    Tuberculosis Control Plan 
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6.  Respirator training shall include:  an explanation of the operation, capabilities and limitations 
of the respirator provided; instruction in how the respirator wearer should inspect, don, fit 
check, and correctly wear their provided respirator; an opportunity for each wearer to handle 
the respirator, learn how to don and wear it properly (i.e., achieve a proper face-seal fit on 
the wearer's face) and check important parts; explanation of why a particular type of 
respirator was chosen, the need for re-evaluation when there is a change in facial hair or 
facial structure,  how the respirator is properly maintained and stored, and the capabilities 
and limitations of the respirator provided; and instruction in how to recognize an 
inadequately functioning respirator.   
7.  HCWs may use either reusable or disposable TB respirators when entering Airborne 
Precautions rooms.  Environmental Health and Safety and the UNC Department of 
Environment, Health and Safety will provide a list of approved reusable TB respirators for 
use by HCWs.  The manufacturer's recommendations regarding care and timing of filter 
replacements should be followed for reusable respirators.  It will be the responsibility of the 
person using the reusable respirator to adhere to the appropriate maintenance program.  In 
general, reusable respirators should be cleaned after use in a Contact Precaution room, 
daily or when visibly soiled with 70% alcohol.  Replacement filters for reusable respirators 
will be available through Central Distribution.      
8.  Respirator inspection, cleaning maintenance, and storage:  Manufacturer's instructions for 
inspection, cleaning, and maintenance of respirators should be followed to ensure that the 
respirator continues to function properly.  Disposable TB respirators may be used as long as 
the respirator continues to pass the fit check and the exterior surface has not become 
contaminated. Damaged or visibly soiled respirators should be immediately disposed of in a 
regular waste receptacle.  Respirators should be immediately disposed of following each 
use when the patient is on Contact Precautions.       
9.  The Respiratory Protection Program will be evaluated at least annually.  Elements of the 
program that should be evaluated include work practices and acceptance of respirators, 
including comfort and interference with duties. 
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Appendix 1:  Abbreviations and Definitions 
 
ABBREVIATIONS 
AIDS  Acquired immunodeficiency syndrome 
BCG  Bacillus of Calmette and Guerin 
CF Cystic  fibrosis 
HCW Healthcare  worker 
HEPA  High-efficiency particulate air 
HIV-1 Human-immunodeficiency  virus 
IGRA  Interferon-gamma Release Assay   
INH Isoniazid 
LTBI  Latent TB Infection 
MDR Multiple-drug  resistant 
NTM Nontuberculous  mycobacteria 
OHP   Occupational Health Provider 
PCR Polymerase  chain  reaction 
TB  Mycobacterium tuberculosis 
TST Tuberculin  Skin  Test 
UV Ultraviolet 
XDR   Extreme drug resistant 
 
 
DEFINITIONS 
 
Aerosols 
Aerosols refer to the suspension in air of solid particles (e.g., tuberculous bacteria) 
Airborne Precautions (for known or suspected active tuberculosis)   
Airborne Precautions (for known or suspected active tuberculosis) requires the use of specialized 
respiratory protection devices and engineering controls designed to minimize the potential for cross-
transmission of M. tuberculosis.  Rooms used to house known or suspected TB patients on Airborne 
Precautions must meet the following criteria: private room, negative pressure with respect to the 
corridor, air directly exhausted to the outside, and >6 air exchanges per hour (≥12 air exchanges per 
hour for new construction).   
Anergy   
Patients who exhibit anergy demonstrate no reaction to all skin tests (TST, mumps, candida, tetanus).  
Anergy may mean that the patient has overwhelming infection with M. tuberculosis and/or depressed 
cell-mediated immunity due to another medical disorder (e.g., sarcoid, HIV-infection).    
BCG   
BCG (bacillus Calmette-Guerin) is a live attenuated strain of tubercle bacilli used in both the U.S. and 
some parts of the world to immunize subjects.  It provides partial protection against the acquisition of M. 
tuberculosis and subsequent development of disease.  It is administered by intradermal inoculation or 
scarification.  In immunocompromised hosts it may rarely cause disease indistinguishable from that 
caused by M. tuberculosis.  
 
   Tuberculosis Control Plan 
IC 0060    Page 24 of 47 
Cough Inducing Procedures   
Procedures that involve instrumentation of the lower respiratory tract or induce cough may increase the 
probability of droplet nuclei being expelled into the air.  These cough inducing procedures include 
endotracheal intubation and suctioning, diagnostic sputum induction, aerosol treatments (including 
pentamidine therapy), and bronchoscopy.  Other procedures that may generate aerosols (e.g., irrigation 
of tuberculous abscesses, homogenizing or lyophilizing tissue, autopsy) may increase the probability of 
droplet nuclei being expelled into the air.  In these cases, the guidelines indicated for aerosol-inducing 
procedures should be followed.   
Exposure   
Healthcare worker, patient and visitor exposure is defined as meeting one of the criteria below when a 
patient is known to have active infection with M. tuberculosis (pulmonary, laryngeal, open wound).  If 
evaluation of exposed HCWs reveals TST conversion or if the patient has an MDR or XDR TB, less 
intensively exposed persons will be evaluated as determined by the Occupational Health Provider.  
Exposed patients will be evaluated by their attending physician and exposed visitors and outpatients 
will be referred to the local health department. 
Exposure criteria: 
1.  Healthcare workers without a mask who were exposed during a cough-inducing procedure. 
2.  Healthcare workers without a mask who cared for the patient in the following environments: 
•  ≥ 8 hours cumulative time in confined airspace 
•  Any exposure to patient with MDR/XDR TB.  
Healthcare Worker (HCW) 
The term HCW refers to all paid and unpaid persons working at UNC Health Care, Ambulatory Care 
Clinics, Campus Health Services, School of Dentistry, and their off-site facilities who have the potential 
for exposure to M. tuberculosis, including, but not limited to: physicians; nurses; aides; technicians; 
laboratory, morgue, funeral home, and dental workers; emergency medical responders; students; part-
time personnel; temporary staff not employed by UNC Health Care; and persons not directly involved 
with patients but who have potential occupational exposure to M. tuberculosis (e.g., dietary, 
housekeeping, maintenance and physical plant employees, clerical, janitorial staff, Health and Safety 
personnel, and volunteers).  Healthcare workers will be considered to be at risk of occupationally 
acquired TB if they have direct contact with patients as part of their employment duties.  Direct contact 
is defined as entering patient care rooms, conversing in person with patients in a common area, or 
face-to-face contact. 
HEPA Filter 
HEPA filter refers to a filter with the ability to capture 99.97% of submicron particles in diameter in a 
single pass.  HEPA filters may be used in ventilation ducts, as components of a portable room 
ventilation device or employed as respiratory protection devices. 
 
Hospital Epidemiology 
Hospital Epidemiology refers to the Department of Hospital Epidemiology (Infection Control) of UNC 
Hospitals. 
Interferon-gamma Release Assay (IGRA) 
IGRA is a blood test for use as an aid in diagnosing M. tuberculosis infection, including latent 
TB and tuberculosis disease. Tuberculosis Control Plan 
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Multidrug Resistant (MDR) / Extensively Drug Resistant (XDR) 
Isolates of M. tuberculosis will be considered multidrug resistant if they are resistant to isoniazid and 
rifampin.  Isolates of M. tuberculosis will be considered extensively drug resistant if they are resistant to 
both isoniazid and rifampin as well as resistant to any fluoroquinolone, and at least one of three 
injectable second-line drugs (capreomycin, kanamvcin, and amikacin). 
Mycobacterium 
Mycobacteria refers to a group of microorganisms.  These include M. tuberculosis complex (M. 
tuberculosis, M. bovis, M. africanum, Bacillus Calmete-Guerin), the agent that causes tuberculosis, and 
a variety of nontuberculous (NTM) mycobacteria.  NTM may cause illness in humans, including 
pulmonary disease and systemic disease, especially in patients infected with HIV.  NTM are acquired 
from the environment and not via person-to-person spread.  Airborne Precautions are NOT required for 
patients infected with NTM (e.g., Mycobacterium avium complex or MAI). 
Occupational Health Provider (OHP) 
Occupational Health Provider refers to Occupational Health Service (OHS) of UNC Health Care and 
University Employee Occupational Health Clinic (UEOHC) of the University. (Students receive care 
from Campus Health Services.) 
Outbreak Investigation 
An outbreak investigation refers to the investigation of possible nosocomial transmission of M. 
tuberculosis between patients, patients and HCWs, or among HCWs. 
Portable HEPA Unit 
A portable HEPA unit is a machine capable of cleansing air through a filter with 99.97% efficiency for 
removing particles of 0.3-5 microns in diameter in a single pass. 
Respiratory Protection 
Respiratory protection refers to use of National Institute of Occupational Safety and Health-approved 
TB respirators by employees when entering rooms of patients known or suspected to have tuberculosis 
and when performing cough-inducing procedures on individuals who have known or suspected 
tuberculosis.  
TST - Tuberculin Skin Test 
TST (made of a purified protein derivative) is an agent used in skin test preparations to aid in 
determining whether persons have been infected with M. tuberculosis.  This agent is injected 
intradermally at a dose of 5 tuberculin units (5 TU).  A "positive" reaction indicates tuberculous infection 
but does not necessarily imply disease.  Skin reactions of a small size may also result from a person's 
prior exposure to NTM.  Placing a TST does not require Airborne Precautions unless active TB is in the 
differential diagnosis and/or AFB smears/cultures are ordered. 
Tissue Test 
A tissue test is performed to assess negative pressure in Airborne Isolation Rooms.  The tissue test is 
performed in the following manner: hold a thin (e.g., 1” x 4”) single-ply strip of tissue along the bottom of 
the isolation room door at the corridor.  If negative pressure is present, the tissue should be drawn 
under the door toward the patient’s room. 
Tuberculosis Infection 
Refers to persons infected with M. tuberculosis as evidenced by a positive TST or reactive blood test 
but without evidence of active disease (tuberculous disease).  People with latent TB infection do not 
transmit the disease to others.   
Tuberculous Disease Tuberculosis Control Plan 
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Refers to persons with evidence of active disease due to M. tuberculosis.  Such evidence includes, but 
is not limited to, the following: a chest radiograph with evidence of active tuberculosis, a sputum smear 
with evidence of tuberculous bacteria, a culture of M. tuberculosis from any body site, and a positive 
TST or tuberculosis blood test with symptoms of active infection.  Such symptoms include, but are not 
limited to, fever, weight loss, night sweats, cough, hemoptysis, and chills.  People with tuberculous 
disease are considered infectious.   
University Employee 
University employee refers to any employee of UNC-CH who works in the Hospitals, Ambulatory 
Clinics, Campus Health Services, or the School of Dentistry.  This term and this exposure control plan 
do not apply to other employees of UNC-CH.   
Volunteer   
Volunteer refers to persons recruited, oriented and trained by the Department of Volunteer Services to 
perform assigned volunteer activities. 
 Tuberculosis Control Plan 
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Appendix 2:  UNC Health Care AFB Laboratory Procedures 
 
I.   Routine Procedures  
 
A.   Smears: Specimens are picked up from the Microbiology Central Processing area every 
morning, Monday through Friday. In order for AFB specimens to be processed that 
morning, they should be received by 8:00 a.m., Monday through Friday. If the patient is 
admitted to UNC Hospitals and placed on Airborne Precautions after 8 a.m., a sputum 
specimen collected on the first day after 8 a.m. will be accepted for smear and culture 
examination but it will not be processed until the next working day. Routine setup includes 
1 LJ slant, BD MGIT (mycobacterial growth indicator tube), and a smear. Smears are to be 
ready for staining by 1:00 p.m. and read and reported by 5:00 p.m.  
1.   Negative smears are resulted to the computer.  
2.   Positive smears are resulted to the computer. Additionally, records are checked on 
these patients for previous positives.  
a.  First positive - notify physician and Epidemiology, send report to state TB 
control. 
b.  Previous positive, -. Notify physician if greater than one year since previous 
positive. 
B.   Cultures:  
1.   BD MGIT bottles are read every hour for 6 weeks for indication of growth. When 
resulted as positive, some of the medium from the bottle is stained with Kinyoun 
stain to look for the presence of AFB. It is also subcultured to a 7H11 plate.  
a.    Stain results are recorded in the computer. Notification of physician, 
Epidemiology, etc., is the same as for smears.  
b.   Proceed to identification.  
2.   LJ slants are read once a week. Results are recorded in the computer. If growth 
is seen, it is stained for the presence of AFB by Kinyoun stain.  
a.    Positive Kinyoun stains are recorded in the computer. Notification of 
physician, Epidemiology is the same as for smears.  
b.   Proceed to identification.  
3.   Identification: Check morphology on solid media (7H11 or LJ):  
a.  Proceed to 16S rRNA or hsp65 gene sequencing for identification of 
mycobacterial isolate based on colony morphology.  
b.  Results are recorded on the computer. Notification of physician, 
Epidemiology, etc., is the same as for smears, if identification is M. 
tuberculosis Complex (M.tb).  
c.  Send ID to TB control on all first time positive isolates of M.tb.  
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C.   Susceptibility testing:  
1.   Fluorometric  susceptibility testing to streptomycin, isoniazid, rifampin, 
pyrazinamide, and ethambutol, is done for all new M.tb. isolates and any isolates of 
M.tb following 3 months of treatment. Susceptibility testing takes 5-21 days  to 
complete following inoculation of the test.  
2.  Conventional susceptibility (proportion method) testing is performed on M.tb. 
isolates that are resistant to any drug on the flurometric  panel. Drugs on the 
conventional panel include streptomycin, isoniazid, rifampin, ethambutol, 
capreomycin, ciprofloxicin, kanamycin, cycloserine, para-amino salicylic acid, 
thiacetazone, and ethionamide. This testing is currently performed at the North 
Carolina State Health Laboratory and requires a minimum of an additional three 
weeks. 
3.  Additional drugs for susceptibility testing may be requested and will be performed 
at a reference laboratory.  
4.  In the case of drug resistant M. tb. isolates, the requesting physician, 
Epidemiology, and the State and local health departments will be notified.  
II.   Special Requests  
 
A.        STAT AFB smears are not routinely performed.  Approval must be sought from the On-
Call Director of Clinical Microbiology, who may be reached by contacting the laboratory 
(966-4053).  In many cases (e.g. weekend or holiday staffing) only a direct smear (not 
concentrated) will be performed, which has a very low sensitivity. A culture and smear 
from the concentrated specimen will be performed at the next scheduled routine run.  
B.        DNA sequencing:  Species identification by DNA sequencing, although usually performed 
from growth on solid media, may be done (once the bottle is positive) from a positive MGIT 
bottle. Inconclusive results may arise from this practice, and sequencing will be repeated 
from solid media growth, resulting in additional charges. Tuberculosis Control Plan 
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Appendix 3:  UNC Health Care Occupational Health Service Submission Form for Outside 
Tuberculin Skin Testing 
 
Employee Name:_____________________________SS#___________________ 
Department_________________________________ 
 
Tuberculin skin testing (TST) and a review of personnel for potential symptoms of Tuberculosis is 
recommended by the Centers for Disease Control and Prevention for all healthcare personnel at least 
annually.  It is the policy of the UNC Health Care to require all employees to have a review of potential 
symptoms during their birth month unless contraindicated.  Tests performed by other healthcare 
professionals will be accepted provided this form is fully completed, and the form is signed and dated 
by a healthcare professional (nurse, physician, physician extender).  Only a 5sTU-TST skin test 
performed by the Mantoux method and read 48-72hours after placement is acceptable (unless 
contraindicated). The skin test must be performed by a department/office trained in public 
health/Occupational Medicine (e.g. Student Health Service, Public Health Department, Employee 
Health Service of other hospitals, private physician office, military).  Please be aware that this form will 
be reviewed by OHS and a follow-up visit may be required. 
TB blood test is also accepted with proper documentation (see below) 
 
SYMPTOM EVALUATION: TO BE COMPLETED BY THE EMPLOYEE 
Have you had any of the following in the last month? 
 
Fever    Yes___No___   Cough(>3  weeks)   Yes___No___ 
Chill    Yes___No___   Weight  loss>10lbs   Yes___No___ 
Night sweats     Yes___No___   Sputum production    Yes___No___ 
Fatigue  Yes___No___   Blood  in  sputum   Yes___No___ 
 
TST or TB blood test: TO BE PERFORMED BY A HEALTHCARE PROFESSIONAL (form to be 
completed by a healthcare provider placing and evaluating the TST- employees may not place 
or interpret their own skin tests). 
 
TST Manufacturer:_________________________Lot Number__________________ 
Strength:____________(5sTU) 
Date applied___________________ Date read_______________________________ 
Induration(mm)_________________ Redness (in mm)_________________________ 
Placed by:________________________Read by:_____________________________ 
Title__________________Signature(required)________________________________ 
Institution and Address___________________________________________________ 
 
TB blood test Manufacturer__________________Date obtained___________________ 
Result________________ 
Title____________________Signature (required)_______________________________ 
Institution and Address____________________________________________________ 
Please FAX to UNC Occupational Health Service:  (919) 966-6326 Tuberculosis Control Plan 
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Appendix 4:  Summary of Interpretation of Skin Tests 
 
1.     A reaction of > 5 mm is classified as positive in: 
• HIV-positive  persons 
•  Recent contacts of TB case 
•  Fibrotic changes on chest radiograph consistent with old TB 
•  Patients with organ transplants and other immunosuppressed patients (receiving the 
equivalent of > 15 mg/d Prednisone for > 1 mo) 
 
2.     A reaction of >10 mm is classified as positive in all persons who do not meet any of the criteria 
above but do have other risk factors for TB including: 
•  Recent arrivals (< 5 yr) from high-prevalence countries 
•  Injection drug users 
•  Residents and employees* of high-risk congregate settings: 
                      prisons and jails, nursing homes and other healthcare facilities, residential 
                      facilities for AIDS patients, and homeless shelters 
•  Mycobacteriology laboratory personnel 
•  Persons with clinical conditions that make them high-risk: silicosis diabetes mellitus, chronic 
renal failure, some hematologic disorders (e.g., leukemias and lymphomas), other specific 
malignancies (e.g., carcinoma of the head or neck and lung), weight loss of > 10% of ideal 
body weight, gastrectomy, jejunoileal bypass 
•  Children < 4 yr of age or infants, children, and adolescents exposed to adults in high-risk 
categories 
 
3.     Induration of  > 15 mm is classified as positive for persons with no risk factors for TB. 
 
 
* For persons who are otherwise at low risk and are tested at entry into employment, a reaction of > 15 mm induration is 
considered positive.   Tuberculosis Control Plan 
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Appendix 4-1:  Occupational Health Service Evaluation of Reactive TST (≥5 mm induration at 48-
72 hours) 
1.  Birth  date          -   -    
2a.  Most recent TST (date placed)         -   -   
2b.  Size  (in  mm)           by    
3a.  Previous TST (date placed)           -   -   
3b.  Size  (in  mm)           by    
 
If symptoms of active TB are present, evaluation for active TB with stat chest radiograph and 
expectorated sputum for AFB smear plus culture (x3 in ID Clinic).  IMMEDIATELY PLACE ON 
AIRBORNE ISOLATION AND FURLOUGH FROM WORK. 
 
4.  Determination  of  Risk  Status         Circle 
a.  HIV+ and recent close contacts to known or suspected infectious TB disease     
  regardless of previous preventive therapy             Y    N   
b.  HIV+ and CxR suggestive of previous TB who has received inadequate or  
      no therapy                    Y    N 
c .   H I V   i n f e c t i o n            Y         N  
d.  Close contact (household) to known or suspected infectious TB disease    Y    N 
e.  Persons who inject drugs or use crack cocaine          Y    N 
f.  Recent seroconverter (>10mm increase within 2 year period of time)    Y    N 
g.  Diabetes mellitus (insulin requiring)              Y    N 
h.  High-dose steroids (prednisone >15mg daily for >4 weeks)       Y    N 
I.  Immunosuppressive  therapy         Y        N 
j.  End stage renal disease (dialysis)              Y    N 
k.  Leukemia, lymphoma, Hodgkin’s disease            Y    N 
l.  Cancer of the head or neck                Y    N 
m.  Weight loss of >10% ideal body weight            Y    N 
n.  Silicosis           Y        N 
o.  Gastrectomy or jejunoileal bypass              Y    N 
p.  Foreign-born arriving in U.S. within past 5 years from Asia, Africa, Caribbean, 
  Latin America, Mexico, South America, or Pacific Islands        Y    N 
5.  Chest radiograph      -   -       Abnormal  Y    N 
Screening Completed by: ________________________________  Date: ___________________ 
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6.  Determination of Need for Treatment of Latent TB      Circle 
  a.  TST, > 5mm  
  1 )     H I V   i n f e c t i o n   ( 4 c )            Y         N  
    2)  Close contact to recent active TB (4d)           Y    N 
    3)  Abnormal CxR (fibrotic changes) suggestive of old TB (5)    Y    N 
  b.  TST, >10mm  
  1 )     I D U   ( 4 e )             Y         N  
  2)    Seroconverter  (4f)           Y        N 
    3)  Medical risk factor (4g-4o)             Y    N 
    4) Foreign immigrant (4p) 
    4)  HCW working in low, intermediate, high risk area      Y    N 
    5)  Mycobacteriology lab personnel            Y    N 
  c.  TST, >15mm 
    1) Persons with no risk factors for TB           Y    N 
    2) HCW working in minimal or very low risk locations      Y    N 
If patient meets above criteria for treatment of latent TB obtain the following: 
7.  Contraindications to therapy (fill in letter)                        
  a.  Anaphylaxis or adverse reactions to INH in past 
  b.  Heavy ethanol consumption 
  c.  Underlying liver disease (e.g., HCV) 
  d.  Expected poor compliance 
  e.  Other (pregnancy is not a contra-indication 
  f.  Anaphylaxis to PZA or rifampin 
 g.  Contact  lens 
 
8.  Patient  accepts  INH          Y        N 
9.  Reasons for refusal of therapy (fill in letter)              
  a.  Pregnant or plans to become pregnant 
 b.  Contraindication 
  c.  Concerned about side effects 
  d.  Refusal, no reason given 
 
10.  Risks and benefits explained to patient            Y    N 
11.  HIV testing offered to patient                Y    N 
12.   HIV Consent signed by patient              Y    N   
 
Physician/Nurse Practitioner opinion regarding therapy _____________________________________ 
 
_________________________________________________________________________________ 
 
Employee notified by who: __________________________  Date ________________________ 
 
Signature (MD/FNP) _______________________________  Date _________________________ Tuberculosis Control Plan 
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Appendix 5:  Protocol for Early Identification of Patients with Suspected Tuberculosis - 
Ambulatory Care and Community-Based Centers 
 
Patient Check-In / Waiting Process 
•  Front line personnel (front desk, information and front door staff) should identify patients with 
symptoms (see below) that may indicate potential tuberculosis, and immediately notify the charge 
nurse. 
•  Front line personnel should note if there are comments associated with the appointment regarding 
the patient having symptoms/conditions that indicate that the patient may have tuberculosis.  These 
patients should be brought to the attention of nursing personnel for further assessment. 
•  Front line personnel should offer tissues to all patients with coughs and encourage the patient to 
cover his/her mouth and nose with a tissue when coughing or sneezing.  Nursing staff should be 
notified of patients who are coughing excessively. 
•  Patients who have respiratory symptoms and report any of the following high-risk situations should 
be brought immediately to the attention of the nursing staff for further evaluation. 
•  Patients with known or suspected active pulmonary tuberculosis should be given a surgical mask to 
wear and placed in an exam room. 
 
Medical conditions that may indicate tuberculosis include a cough for more than three weeks, especially 
if any of the following are present: 
  Profound  fatigue 
  Unintentional  weight  loss 
  Night  sweats 
  Fevers 
  Hemoptysis  (bloody  sputum) 
    Anorexia (loss of appetite) 
 
Historical facts which increase the risk for pulmonary tuberculosis: 
    Exposure to others with active tuberculosis 
    History of a positive skin test (TST) 
    History of therapy with anti-tuberculosis drugs 
  HIV  infection 
    Immigrants from countries in Africa, Asia or South America 
  Migrant  farm  workers 
    Persons who are or have recently been incarcerated 
  Homeless  individuals 
 
Nursing Assessment:  Nursing personnel (if not available, a physician) are responsible for evaluating 
patients who display symptoms or signs of active tuberculosis or are at high risk for active tuberculosis. 
 
•  Nursing personnel should review the medical record of any patient at high risk for active pulmonary 
tuberculosis to determine if symptoms that could indicate active tuberculosis are present. 
•  Nursing personnel should immediately assess patients with symptoms suggestive of tuberculosis 
when notified by front line personnel.  Patients should be removed from the waiting area and placed 
in an exam room (preferably in a room meeting TB isolation requirements-Airborne Precautions 
room with negative pressure and out exhaustion). 
•  If the room does not meet OSHA AFB standards, then the patient should be provided with a 
surgical mask and shown how to wear the mask properly (i.e., it must cover nose and mouth).  Staff 
will don a respirator.  Arrangements should be made to transfer the patient as soon as possible to 
the ACC Medical-Pulmonary Clinic, Hematology Oncology Clinic, Emergency Department, the Tuberculosis Control Plan 
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Hospital Infectious Diseases Clinic, Pediatric Specialty Clinic or the local health department for 
further evaluation of active tuberculosis.  For example, suspect TB patients in the ACC should go to 
the Medicine Pulmonary Clinic in the ACC, suspect TB patients in the main hospital clinics should 
go to the Infectious Disease Clinic, and suspect TB patients in the Gravely Building should go to the 
Hematology-Oncology Clinic in the Gravely Building.  Pre-Care has a negative pressure room for 
evaluation of pre-op surgical patients and the ED has two negative pressure rooms for emergency 
room patients.  Pediatric patients should be sent to the Pediatric Specialty Clinic negative pressure 
room # 3.  Patients seen at Community Based Centers should be referred to the local health 
department for further evaluation and follow-up.  If the patient leaves the room for any reason (e.g., 
to obtain a chest radiograph) he/she must wear the surgical mask. 
•  Patients with signs or symptoms suggestive of active tuberculosis should be evaluated as rapidly as 
feasible, in an appropriate airborne isolation room. 
•  Nursing personnel should notify the physician as rapidly as feasible, that the patient may have 
active tuberculosis. 
•  All personnel entering a room of a patient with known or suspected active tuberculosis should wear 
an N-95 respirator. 
•  Patients waiting for an inpatient bed should not wait in the admitting office but be placed in an 
appropriate Airborne Isolation room in clinic until a bed becomes available. Tuberculosis Control Plan 
IC 0060    Page 35 of 47 
Appendix 6:  N-95 Particulate Respirator - OSHA Respirator Medical Evaluation 
Questionnaire 
(Adopted from 29 CFR 1910.134, Appendix C, January 8, 1998) 
UNIVERSITY EMPLOYEE OCCUPATIONAL HEALTH CLINIC 
Note to employee: Your employer must allow you to answer this questionnaire during normal working hours, or 
at a time and place that is convenient to you. To maintain your confidentiality, your employer or supervisor must 
not look at or review your answers, and your employer must tell you how to deliver or send this questionnaire to 
the healthcare professional who will review it. This form must be completed by the employee as well as signed 
and approved by a healthcare professional, before an employee can be fit-tested to wear a respirator. Should you 
have any questions about this form or about your ability to safely wear a respirator, please call UEOHC at 966-
9119. 
 
NAME ______________________________   AGE_______    BIRTH DATE______________ 
 
PID________________________  SEX_________  HEIGHT________   WEIGHT__________ 
 
JOB TITLE___________________________ DEPT_________________________ CB#____________ 
PHONE_______________________   BEST TIME TO PHONE________________________________ 
 
HAS YOUR EMPLOYER TOLD YOU HOW TO CONTACT THE HEALTHCARE PROFESSIONAL 
WHO WILL REVIEW THIS QUESTIONNAIRE:                  YES         NO 
CHECK THE TYPE OF RESPIRATOR YOU WILL USE:    N-95      OTHER(specify)______________ 
SUBSTANCE NECESSITATING RESPIRATORY USE: TUBERCULOSIS OTHER_____________ 
HAVE YOU EVER WORN A RESPIRATOR?   YES   NO   If yes, what type?__________________ 
PLEASE ANSWER THE FOLLOWING NINE QUESTIONS                                                        YES        NO 
1.  Do you currently smoke tobacco, or have you smoked tobacco in the last month?     
 
2.  Have you ever had any of the following conditions?     
     a.  Seizures (fits)    
     b.  Diabetes (sugar disease)    
     c.  Allergic reactions that interfere with your breathing     
     d.  Claustrophobia (fear of closed-in places)     
     3.  Trouble smelling odors    
 
3.  Have you ever had any of the following conditions?     
     a.  Seizures (fits)    
     b.  Asthma    
     c.  Chronic bronchitis    
     d.  Emphysema    
     e.  Pneumonia    Tuberculosis Control Plan 
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     f.  Tuberculosis    
     g.  Silicosis    
     h.  Pneumothorax (collapsed lung)     
     i.  Lung cancer    
     j.  Broken ribs    
     k.  Any chest injuries or surgeries    
     l.  Any other lung problem    
 
4.  Do you currently have any of the following symptoms of pulmonary or lung illnesses?     
     a.  Shortness of breath    
     b.  Shortness of breath when walking fast on level ground or walking up a slight hill or incline     
     c.  Shortness of breath when walking with other people at an ordinary pace on level ground     
     d.  Have to stop for breath when walking at your own pace on level ground     
     e.  Shortness of breath when washing or dressing yourself     
     f.  Shortness of breath that interferes with your job     
     g.  Coughing that produces phlegm (thick sputum)     
     h.  Coughing that wakes you early in the morning     
     i.  Coughing that occurs mostly when you are lying down     
     j.  Coughing up blood in the last month     
     k.  Wheezing    
     l.  Wheezing that interferes with your job     
    m. Chest pain when you breathe deeply     
    n.  Any other symptoms that you think may be related to lung problems     
 
5.  Have you ever had any of the following cardiovascular or heart problems?     
     a.  Heart attack    
     b.  Stroke    
     c.  Angina    
     d.  Heart failure    
     e.  Swelling in your legs or feet (not caused by walking)     
     f.  Heart arrhythmia (heart beating irregularly)     
     g.  High blood pressure    
     h.  Any other heart problem    
 
6.  Have you ever had any of the following cardiovascular or heart symptoms?     
     a.  Frequent pain or tightness in your chest     
     b.  Pain or tightness in your chest during physical activity     
     c.  Pain or tightness in your chest that interferes with your job     
     d.  In the past 2 years, have you noticed your heart skipping or missing a beat      Tuberculosis Control Plan 
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     e.  Heartburn or indigestion that is not related to eating     
     f.  Any other symptoms that you think may be related to heart or circulation problems     
 
7.  Do you currently take medication for any of the following problems?     
     a.  Breathing or lung problems    
     b.  Heart trouble    
     c.  Blood pressure    
     d.  Seizures (fits)    
 
8.  If you’ve ever used a respirator, have you ever had any of the following problems? 
     If you’ve never used a respirator, check the following space and go to question 9   
   
     a.  Eye irritation    
     b.  Skin allergies or rashes    
     c.  Anxiety    
     d.  General weakness or fatigue    
     e.  Any other problem that interfered with your use of a respirator; if yes, specify:     
 
9.  Would you like to talk to the healthcare professional who will review this questionnaire about your 
answers to this questionnaire? 
  
 
Employee signature_______________________________________     Date__________________ 
Medical assessment for respirator use:   No restrictions      No use permitted 
                                                     Specific restrictions____________________________________ 
Form reviewed by _____________________________________  Date _______________________  
 Tuberculosis Control Plan 
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Appendix 6-1:  Respirator Medical Evaluation Form 
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Appendix 6-2:  UNC Health Care Occupational Health Service Respiratory Protection Data 
 
NAME:_________________________________  MEDICAL RECORD #:___________________ 
 
DEPARTMENT:__________________________ SOCIAL SECURITY #:____________________ 
 
Has medical clearance for use of NIOSH-approved respirator: 
Cleared: Yes No 
N-95   
PAPR   
Other   
 
Notes: 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
 
Approved with restriction       Denied  
 
RN/NP/MD Signature:______________________________________ Date:_________________  
 
 
 
 
 
 
White – Occupational Health copy 
Blue – Fit Test Trainer copy 
Yellow – Employee copy Tuberculosis Control Plan 
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Appendix 7:  University Employee Occupational Health Clinic Tuberculosis Screening 
Questionnaire 
 
Name ________________________________ UNC MRN ___________________ AGE ___________ 
 
Dept ___________________Job title ____________________Phone _________ Beeper __________ 
 
 
HAVE YOU HAD ANY OF THE FOLLOWING IN THE LAST MONTH? 
FEVER    YES     NO    COUGH (> 3 WKS)     YES    NO 
CHILLS      YES     NO    WEIGHT LOSS (> 10lbs)   YES    NO 
NIGHT SWEATS     YES     NO    SPUTUM PRODUCTION   YES    NO 
FATIGUE      YES     NO    BLOOD IN SPUTUM     YES    NO 
 
HAVE YOU RECEIVED BCG (vaccination for tuberculosis)?    YES    NO 
 
If yes, where and when? 
_______________________________________________________________________________ 
 
IF YOU’VE HAD A POSITIVE SKIN TEST OR TREATMENT FOR TB, PLEASE ANSWER THE 
FOLLOWING: 
 
Where _____________________________  Date _____________ Size of swelling _______________ 
 
Treatment medication(s)? __________________________________________ # of months _________ 
 
Chest x-ray_________________________________________________________________________ 
 
ALL MEDICAL INFORMATION IS CONSIDERED CONFIDENTIAL.      INDIVIDUALS WITH 
CERTAIN MEDICAL CONDITIONS MAY BE MORE SUSCEPTIBLE TO ACQUIRING INFECTIONS. 
IF YOU HAVE ANY OF THE FOLLOWING CONDITIONS, UEOHC CAN PROVIDE RISK 
REDUCTION COUNSELING. 
If you have any of the following, check here:  
oral steroids (i.e. prednisone); chemotherapy; leukemia, lymphoma, or other cancer; organ transplant; 
immunosuppressive disease (i.e. HIV+, Hepatitis B+); or other conditions which you feel may make 
you more susceptible to infections. 
 
PLEASE TURN FORM OVER AND COMPLETE THE LATEX QUESTIONNAIRE 
 
TO BE COMPLETED BY NURSE: 
 
DATE OF MOST RECENT PRIOR TST AND RESULT: _____________________________________ 
 
REASON FOR TEST:   NEW EMPLOYEE    ANNUAL   EXPOSURE   OTHER_____________ 
 
REASON TST NOT PLACED:    BCG WITH +TST          +TST                HYPERSENSITIVITY                       
 INH PROPHYLAXIS      HISTORY OF TB  
 
 
  Tuberculosis Control Plan 
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Date TST placed __________  By ____________ 
 
Site:   R              L  
 
Lot # _________         Exp date _____________ 
Date TST read ________ By ______________ 
 
Results:  Positive             Negative 
                                  
mm induration _________________ 
 
 
ADDITIONAL NOTES (including comments on any positive responses noted above) Tuberculosis Control Plan 
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Appendix 7-1:  UNC Health Care Occupational Health Service Tuberculosis Screening 
 
NAME:__________________________________ 
 
DEPARTMENT:___________________________ 
 
AGE:____________________________________ 
 
HAVE YOU HAD ANY OF THE FOLLOWING IN THE LAST MONTH? 
 
Fever    Yes___No___   Cough  (for  >3  weeks)   Yes___No___ 
Chills    Yes___No___   Weight  Loss    Yes___No___ 
Night  Sweats   Yes___No___   Sputum  Production   Yes___No___ 
Fatigue  Yes___No___   Blood  in  Sputum   Yes___No___ 
EXPLAIN ALL ANSWERS:____________________________________________________________ 
 
WHEN WAS YOUR LAST TST SKIN TEST__________WHAT WERE THE RESULTS_________ 
 
HAVE YOU RECEIVED BCG (VACCINE FOR TUBERCULOSIS)? 
Yes___No___.If  yes, where and when___________________________________________________ 
 
IF YOU HAVE HAD A POSITIVE SKIN TEST ANSWER THE FOLLOWING: 
Date:____________________________Chest Xray________________________________________ 
Treatment with INH:  Yes___No___Months______________________________________________ 
Treatment with other meds:  Yes___No___Names________________________________________ 
 
TO BE COMPLETED BY OCCUPATIONAL HEALTH NURSE 
 
REASON FOR CURRENT TEST: 
NEW EMPLOYEE___ANNUAL___EXPOSURE________________(NAME/SOURCE) OTHER____ 
 
REASON TST NOT PLACED: 
Hypersensitivity___Positive TST(documented)___BCG with Positive TST(documented) 
INH Prophylaxis___ 
 
CURRENT TEST: 
DATE:___________________________    DATE:_____________________________ 
TST_______________LOT#_________    READ:____________MM__________MM 
RFA_______________LFA__________    SIGN______________________________ 
SIGN____________________________ 
 
DATE:___________________________    DATE:_____________________________ 
TST_______________LOT#_________    READ:____________MM__________MM 
RFA_______________LFA__________    SIGN______________________________ 
SIGN____________________________Tuberculosis Control Plan 
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Appendix 8:  Occupational Health Algorithm for Multidrug Resistant TB Exposures 
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Appendix 9:  Procedure for Instituting Airborne Precautions When the Patient is Housed 
in a Multi-Bed Room 
 
At times the decision to exclude tuberculosis (TB) will be made for a patient housed in a multi-bed room 
(e.g., semi-private).  In this situation it is important that the nursing staff take measures to protect the 
roommate, the visitors, and the UNCHC staff from further exposure until the suspect TB patient can be 
moved to an appropriate Airborne Isolation room.  It is also important to protect the privacy of the 
suspect TB patient while communicating with the roommate regarding the institution of Airborne 
Precautions and the follow-up that will occur should their exposure to a communicable disease be 
confirmed.   
 
When the physician orders Airborne Precautions to rule out tuberculosis in a patient housed with a 
roommate in a multi-bed room: 
 
1.   Place a surgical mask on the suspect TB patient. 
2.   If for some reason the patient cannot tolerate wearing a mask, instruct the patient to cover all 
coughs and sneezes with a tissue.  If the patient breathes through a tracheostomy, loosely tie a 
surgical mask over it.   
3.   Close the curtain between the patients. 
4.   Keep the door to the room closed. 
5.   Page the house supervisor to inform her that the patient must be moved to an approved Airborne 
Precautions room as soon as possible, preferably within 1 hour. 
6.   If there will be a delay of more than 2 hours in moving the suspect TB patient, move either the 
suspect TB patient to a private room on the unit or move the roommate to another private or multi- 
bed room on the unit, if possible. 
7.   Obtain a HEPA unit from Patient Equipment and place it in the room near the source patient. 
8.   Place the Airborne Precautions sign outside the room, along with N95 respirators in 2 sizes.  
Surgical masks should be available outside the room for visitors. 
9.   Visitors should be excluded until 30 minutes after the source patient has been transferred out of the 
room.  The Airborne Precautions sign states, “Visitors must report to the nursing station before 
entering.”   
10. The source patient’s roommate should be informed as follows:  “Your roommate’s physician is 
ruling out a communicable disease.  In the unlikely event the patient actually has a communicable 
disease, your physician will be contacted by our Infection Control Department.  Your doctor will 
provide advice regarding any follow-up that may be needed.”   
11. Call the Infection Control Professional (ICP) on call (pager 216-6652) for any additional questions or 
for any assistance needed to implement this policy.    Tuberculosis Control Plan 
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Appendix 10:  UNC Health Care Guide to Airborne Isolation Precautions for Suspect TB 
Patients 
 Tuberculosis Control Plan 
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Appendix 11:  AFB Biological Spill Procedure 
 
Accidents involving breakage of containers of mycobacterium, a break inside a centrifuge, spilling of 
liquids containing specimen material or liquids known to contain AFB, must all be regarded as 
potentially creating an infectious aerosol and strict precautions must be adhered to.  The protocol below 
should be followed if such a spill should occur in either the AFB Hood room or the main AFB/Mycology 
room.  All areas of Special Microbiology should be included in the evacuation unless the spill is 
contained in the AFB Hood room (which has negative pressure to the rest of the lab).  
The items needed to wear during spill clean up are made up in a kit located in the lab).  The items 
needed to wear during spill clean up are made up in a kit located in room 1027. Report all accident to 
the supervisor and fill out an incident report.  Supervisor will inform Health and Safety, HVAC, and 
Departmental Safety Coordinators. 
 
1.   IMMEDIATELY EVACUATE THE ROOM. 
2.   Close and lock the doors and mark “DO NOT ENTER” on all entryways affected.  Do not reenter for 
at least 2 hours. 
3.   After at least 2 hours, enter the room wearing protective clothing including an aerosol-protective 
respirator, gown, booties, gloves, and safety goggles. 
4.   Place towels over the spill and soak with tuberculocidal disinfectant (Metriguard).  Let soak for at 
least 2 hours. 
5.   Reenter the room wearing protective clothing as above and carefully clean up the spill and mop 
floors and countertops with 10% bleach.   
6.   Properly dispose of and disinfect all material used in decontamination and autoclave any clothing 
that may have become contaminated. 
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